首页> 美国卫生研究院文献>European Journal of Human Genetics >Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome intwo patients with atypical teratoid and rhabdoid tumor
【2h】

Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome intwo patients with atypical teratoid and rhabdoid tumor

机译:深内含子热点变异解释横纹肌肿瘤易感综合征在两名非典型畸胎瘤和横纹肌瘤患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

About one third of patients with rhabdoid tumors (RT) harbor a heterozygous germline variant in SMARCB1. Molecular diagnosis therefore keeps a crucial place in the diagnosis of RT, and genetic counseling should be systematically recommended. However, immunohistochemistry has progressively replaced molecular tools to assess the status of SMARCB1 in tumors; the necessity of analyzing SMARCB1 status in the tumor may thus be less considered by neuropathologists and pediatric neuro-oncologists. In the present manuscript as aforementioned, we report on two patients with bifocal RT in the first month of life and in whom no germline variant was initially found in the SMARCB1 coding sequence. Careful analysis of SMARCB1 status in the tumors revealed that only one of the two inactivating hits was found in the coding sequence. By sequencing the tumor cells RNA, we were able to detect an insertion with an abnormal sequence, due to the same intronic variant of SMARCB1, which led to the exonisation of the first intron. This cryptic variant was absent in the germline DNA of both patients. Of note, we previously reported one patient with the same deep intronic variant in the germline in a soft tissue RT. To our mind, this additional report on two patients clearly demonstrates that this intronic variant is a new hotspot that should now besystematically added to the germline screening of SMARCB1. We thereforerecommend searching for and cautiously interpreting germline analysis ifSMARCB1 has not been extensively studied in the tumor.
机译:大约有三分之一的患有横纹肌瘤(RT)的患者在SMARCB1中拥有杂合种系变异。因此,分子诊断在RT的诊断中保持着至关重要的地位,应系统地建议进行遗传咨询。然而,免疫组化已逐渐取代了分子工具以评估SMARCB1在肿瘤中的状态。因此,神经病理学家和儿科神经肿瘤学家可能较少考虑分析肿瘤中SMARCB1状态的必要性。在前面提到的本手稿中,我们报道了两名患者在出生后第一个月出现双焦点RT,并且最初在SMARCB1编码序列中未发现种系变异。仔细分析肿瘤中SMARCB1的状态后发​​现,在编码序列中仅发现了两个灭活基因之一。通过对肿瘤细胞RNA测序,我们能够检测到具有异常序列的插入,这是由于SMARCB1的同一内含子变异导致了第一个内含子的外显子化。两名患者的种系DNA中均不存在这种神秘变异。值得注意的是,我们先前曾报道过一名患者在软组织RT中的种系具有相同的深度内含子变异体。在我们看来,这份关于两名患者的补充报告清楚地表明,这种内含子是一个新的热点,现在应该成为系统地添加到SMARCB1的种系筛选中。因此,我们建议搜索并谨慎解释种系分析,如果SMARCB1尚未在肿瘤中进行广泛研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号